Jaguar Health, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
JAGX Nasdaq 2830 jaguar.health

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Jaguar Health, Inc.

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Nov 14th, 2025 7:00 am
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting - Nov 13th, 2025 7:00 am
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting - Nov 6th, 2025 7:00 am
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 24th, 2025 2:15 pm
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID) - Oct 6th, 2025 7:00 am
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease - Sep 30th, 2025 7:00 am
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Sep 25th, 2025 7:00 am
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition - Sep 24th, 2025 7:00 am
Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream - Sep 24th, 2025 5:00 am
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Sep 23rd, 2025 7:00 am
Jaguar Health Completes Private Placement Deal - Sep 21st, 2025 7:10 am
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts - Sep 5th, 2025 7:00 am
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs - Aug 21st, 2025 7:00 am
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders - Aug 19th, 2025 2:15 pm
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID) - Aug 19th, 2025 7:00 am
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream - Aug 19th, 2025 5:00 am
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue - Aug 14th, 2025 6:00 am
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates - Aug 12th, 2025 7:00 am
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream - Jul 16th, 2025 5:00 am
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Jul 10th, 2025 6:30 am